IQVIA (IQV) fundamentals: P/E, valuation, undervalued?
IQVIA · Health Care · ref. ETF XLV · price $262.38
In short — IQVIA trades at 32.6× earnings (P/E), 18.1× forward, with a net margin of 8.1 % and revenue growth of +9 %. Read: High P/E (P/E 33 (above average)).
Is IQVIA stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$262.38+39.0% over range
Aug 28, 25low $156.66 · high $262.38Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
90% recommend buying · 10 analysts
Valuation : High P/E — P/E 33 (above average)
Valuation
32.6
P/E (price/earnings)
18.1
Forward P/E
—
PEG
7.0
Price/book (P/B)
$43.2B
Market cap
8.06
EPS
Profitability & growth
8.1 %
Net margin
+9 %
Revenue growth
-1 %
Earnings growth
$16.3B
Total debt
IQVIA income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $14.4B | $1.1B | 7.6 % |
| 2023 | $15.0B | $1.4B | 9.1 % |
| 2024 | $15.4B | $1.4B | 8.9 % |
| 2025 | $16.3B | $1.4B | 8.3 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is IQVIA's P/E and is the stock undervalued? What's a good P/E?
IQVIA's P/E is 32.6 (forward 18.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is IQVIA profitable?
IQVIA has a net margin of 8.1 % (EPS 8.06). The company is profitable.
Is IQV stock expensive?
Our read: "High P/E" — P/E 33 (above average). Cross-check with growth and sector.
💬 A question about IQVIA? The JPI assistant answers using our backtest data.